Mutations in the presenilin-1 (PS-1) gene have been shown to cause early onset Alzheimer's disease (EOAD) in an autosomal dominant manner. We have identified a novel 4.6-kb genomic deletion in the PS-1 gene in a Finnish EOAD family, which leads to an inframe exclusion of exon 9 (∆9) from the mRNA transcript. This germline mutation results in a similar alteration in mRNA level as previously described with the variant AD and the ∆9 splice-site mutations. In this present EOAD family, the clinical and neuropathological phenotype of patients are those of the typical AD without indications of spastic paraparesis or 'cotton wool' plaques, which are the hallmarks of the variant AD. A sequence analysis of the deletion crossover site of the mutant and corresponding wild type regions revealed complete homology with the recombigenic 26 bp Alu core sequence at intron 8. In addition, a segment at the intron 9 breakpoint displayed homology with the core sequence, but comparison of the 5' and 3' breakpoint sequences did not reveal significant identity favouring involvement of Alu core sequence-stimulated non-homologous recombination rather than Alu-mediated homologous pairing of the fragments. This study shows that large genomic rearrangements can affect the EOAD gene PS-1 through a mechanism, which may involve Alu core sequence-stimulated recombination.
Introduction
Alzheimer's disease (AD) is the most common cause of progressive neurological disorder leading to dementia. It is neuropathologically characterised by senile plaques and neurofibrillary tangles in the cortex of the brain. The molecular mechanisms leading to AD are not well understood, but it has a genetic etiology, which is most evident in the case of early onset AD (EOAD). To date, highly penetrant mutations in three genes are known to cause autosomal dominant EOAD (onset age before 65 years): amyloid precursor protein (APP) gene on chromosome 21, presenilin-1 (PS-1) gene on chromosome 14 and presenilin-2 (PS-2) gene on chromosome 1. [1] [2] [3] [4] Together, these genes account for approximately 1% of the total AD population while the mutations within the PS-1 gene are more frequently by the cause of EOAD than the mutations in other known genes.
Over 50 different PS-1 gene mutations have been reported in approximately 80 families of various ethnic origins. Nearly all the molecular genetic changes are missense mutations leading to increased production of amyloidogenic A 42 peptide by gain-of-function or dominant-negative mechanism affecting the APP processing. The exceptions are the splice-site mutations resulting in an inframe skipping of exon 9 (∆9) accompanied by a point mutation at the splice junction codon 290 (S290C), and the deletion of exon 9 from the mRNA by an yet undetermined mechanism. [5] [6] [7] [8] In addition, mutation in the intron 4 splice site junction of the PS-1 gene results in two shortened transcripts with premature termination codons and one full-length transcript with insertion of three nucleotides. 9, 10 However, in vivo experiments showed only the presence of the full-length PS-1 protein with one extra amino acid (Thr) in brain extracts and lymphoblast lysates of mutation carriers. PS-1 ∆9 mutations lead to the exclusion of 28 amino acids from the cytoplasmic loop domain of the protein, which contains the endoproteolytic cleavage site. In the normal physiological situation, PS-1 holoprotein undergoes well-controlled proteolytic processing, which produces about 17 kDa carboxyl-terminal and about 28 kDa amino-terminal fragments. Lack of the cleavage site in ∆9 deletions results in the accumulation of uncleaved PS-1 protein. Recently, it was shown that the point mutation (S290C) at the exon 8/10 splice junction rather than the lack of proteolytic processing of PS-1 in the ∆9 mutation, is the cause of the enhancement of pathological functions.
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In this study, we have identified a novel 4.6-kb genomic deletion in the PS-1 gene leading to exclusion of exon 9 in a Finnish EOAD family. AD patients carrying this genomic deletion showed the typical phenotypic features of AD without indications of spastic paraparesis or 'cotton wool' plaques described in the variant AD patients. 8 We suggest
here that the Alu core sequence-stimulated non-homologous event may underlie the genomic rearrangement in this particular EOAD family.
Family and methods

Family
The family had several members with early onset dementia and the transmission of the disease indicated autosomal dominant inheritance ( Figure 1 ). We were able to perform neurological examinations, neuropsychological tests, CT scanning and differential diagnostic laboratory tests for three affected individuals (II:2, II:4 and II:5). For patient II:2, EEG, SPECT, and psychiatric evaluation were made and the patient was diagnosed as having probable AD. Brain biopsy was taken 
Haplotyping
Microsatellite markers D14S77 and D14S1025 were genotyped using fluorescent-labelled PCR-primers obtained from the Genome Database (http://gdbWWW.gdb.org/). PCR amplifications were performed using the standard procedure. 16 The sizes of PCR products were determined with ABI PRISM 310 genetic analyser (Perkin Elmer). Intron 8 polymorphism and E318G substitution in exon 9 were analysed by PCR using mismatch primers and restriction enzyme analysis as previously described by Wragg et al 17 and Dermaut et al, 18 respectively.
RT-PCR analysis
Total RNA was extracted from peripheral lymphocytes using Trizol Reagent (Gibco BRL, Grand Island, NY, USA). Poly (A  + ) mRNA was captured using mRNA Capture Kit (Boehringer Mannheim GmbH, Germany) followed by RT-PCR (Titan™ One Tube RT-PCR System, Boehringer Mannheim) with exons 8 (DEL9F:5'-GCT GTT TTG TGT CCG AAA GGT CCA CTT CGT ATG CTG-3') and 10 (DEL9R: 5'-CTC TGG GTC TTC ACC AGC GAG GAT ACT GCT GGA AAG-3') specific primers ( Figure 3B ). Truncated 261 bp PCR product was excised from 1% low melting agarose gel and cycle-sequenced in both directions (see sequence analysis of PS-1 exons).
Genomic DNA analysis
To define the deletion breakpoint region, PCR reactions were carried out using different primer pairs located at the introns 8 and 9 with Expanded Long PCR System (Boehringer Mannheim). A reaction with primers IN8F4 (5'-AAG TGG TTC ACT CTG GGA GCT TAA C-3') and IN9F5 (5'-GAA AGC TCT TCC TCC ATC CTT CAG C-3') ( Figure 3B ) revealed a novel 1.6-kb PCR-product, which was seen only in the affected member of the family. The PCR-product was cyclesequenced in both directions. For diagnostic purposes, multiplex PCR primers DE8F1 (5'-GTG GAC ATT GAT TTT CAT GTT AC-3'), DE8R2 (5'-TCT AAT ACT CAG GCT TCT TGA AG-3') and DE9R1 (5'-TAT ACC TAC ATG CTC ACA GAC AAT C-3') ( Figure 3B ) were designed on the basis of sequence data to amplify control (504 bp) and deleted (290 bp) fragments. The cycle parameters were 3 min initial denaturation at 94°C followed by 30 cycles at 94°C for 1 min, 52°C for 45 s, and 72°C for 1 min. Alu and other repeat sequences were identified using the BLAST 2.0 program (http:// www.ncbi.nlm.nih.gov/) and the Repeat Masker Server (http://ftp/genome/washington/edu/).
Neuropathology
Cortical biopsy taken in 1992 from the patient II:4 was in two pieces, each approximately 10 mm in diameter. After fixation and paraffin embedding seven-µm thick sections were cut and stained with hematoxylin-eosin, thioflavin-S and modified Bielschowsky silver impregnation. Furthermore, with immunohistochemical stainings, -amyloid aggregates ( A4 -DAKO (Glostrup, Denmark) M872, dilution 1:100; A40 and A42 -US Peptides (New York, NY, USA) 1:1500; 4G8 and 6E10 -Senetek (St. Louis, MO, USA) 1:2000), neurofibrillary tangles (AT8 -Innogenetics (Ghent, Belgium) BR03, 1:500), Lewy inclusions and threads (Synuclein 1, Transduction Lab (Los Angeles, CA, USA) S63320, 1:1000; α-synuclein, ZYMED (San Francisco, CA, USA) LB509, 1:500), reactive astrocytes (GFAP -DAKO Z0334) and activated microglia (HLA DR -DAKO M775) and complement components (C1q -DAKO A0136, C3c -DAKO A0062, C3d -DAKO A0063 and C5 -DAKO A0055, 1:100) were visualised.
Results
A substitution E318G in exon 9, which was recently shown not to relate causally to AD, 18 was detected in two affected cases and in eight healthy individuals by sequencing the coding region of PS-1 ( Figure 1) . No other PS-1 gene alterations were detected. Five out of ten substitution carriers were homozygous for the E318G variant. Segregation of the E318G substitution from the family members to their offspring did not follow normal Mendelian inheritance patterns, since genetic inconsistency was observed in some individuals. To determine the cause of this inconsistency, two microsatellite markers around the PS-1 gene and one biallelic marker located at the 5' end of intron 8 were analysed to construct extended haplotypes. All markers showed a normal segregation pattern. Therefore, the most likely explanation for the non-Mendelian segregation pattern of the E318G substitution was a heterozygous deletion around exon 9, which was defined to start downstream from the biallelic marker of intron 8. Upon further scrutiny, all the AD cases carried the same haplotype 5-2-del-2 for D14S77, intronic polymor- RT-PCR analysis using a lymphocyte sample carrying the presumed disease-associated haplotype 5-2-del-2 was performed ( Figure 2A) . A truncated 261 bp fragment was revealed with PCR-primers located within the exons 8 and 10 ( Figure 3B) , and the sequence analysis of the abnormal RT-PCR fragment showed an inframe deletion of codons 290-319 corresponding to exon 9 (data not shown). In accordance with this result, RT-PCR performed with exon 7 and 12 specific primers produced a truncated fragment lacking the alternatively spliced exon 8 19 and also exon 9 (data not shown). Therefore, abnormal exclusion of the exon 9 from PS-1 cDNA suggested that the breakpoint regions of genomic deletion were located in the introns 8 and 9.
In order to define the deletion breakpoints at the genomic level, long PCR amplifications with intron 8 and 9 specific primers were conducted. A PCR reaction with primers IN8F4 and IN9F5 located approximately 2.7 and 3.3-kb from exon 9, respectively ( Figure 3B ), produced a novel 1.6-kb fragment, which was only seen in the affected family member (data not shown). Diagnostic PCR primers were designed on the basis of sequence data obtained from 1.6-kb product ( Figure 3B ) and the screening of the affected family members showed a heterozygote 290 bp fragment in subjects carrying the haplotype 5-2-del-2 ( Figure 2B ). Sequence analysis of the 290 bp fragment revealed flanking sequences of the deletion. This allowed us to determine that the total deletion was 4555 bp large and consists of 1.6-kb distal part of intron 8, exon 9 and a 2.9-kb proximal part of intron 9 ( Figures 3A and B) . Deletion analysis of 102 AD patients and 51 control subjects from Eastern Finland did not reveal any additional cases with the novel PS-1 ∆9 mutation.
In the neuropathological examination, the HematoxylinEosin staining of the frontal cortex sections visualised both grey and white matter. In the grey matter characteristic lesions for AD, such as amyloid plaques (AP) with a central core formation and neurofibrillary tangles among the neuronal population were observed ( Figure 4A ). Round plaques without cellular participation as described in the entity of variant AD with cotton wool plaques were not seen. Thioflavin-S staining demonstrated several amyloid cores and cerebral amyloid angiopathy (CAA), both in the parenchyme and in the leptomeninges. Bielshowsky silver impregnation demonstrated numerous neurofibrillary tangles, neuritic plaques and senile/amyloid plaques ( Figure 4B ). Alzheimer's degenerative changes were sufficient for the diagnosis of definite AD according to CERAD. 20 Beta-amyloid aggregates were visualized with immunohistochemical staining (Figure 4C ) in the vessel walls of the neuropil and leptomeninges (CAA) and in the neurophil as APs. These APs were quite numerous, round in shape and varied in size. Numerous APs and CAA were labelled with antibodies A4, A42, 6E10 and To avoid alternatively spliced fragments of exon 8 produced in lymphocytes, cDNAs were amplified using exon 8 and 10 specific primers. Truncated 261 bp fragment including the exons 8 and 10 was excised from the agarose gel and sequenced. B DNA analysis of genomic deletion using the intron 8 and 9 specific PCR-primers. Multiplex PCR reactions with primers DE8F1, DE8R2 and DE9R1 were performed to amplify control (504 bp) and deleted fragments (290 bp). The intermediate DNA fragment seen in both AD and control cases was the product of unspecific PCR-amplification.
Novel 4.6-kb genomic deletion in presenilin-1 gene y 4G8 whereas only few were labelled with antibodies against the short A40. Some amyloid aggregates were also detected in the white matter. Numerous neurofibrillary tangles (NFT), neuropil threads (NT) and neurites in neuritic plaques (NP) were visualised with phosphorylated PHF-Tau antibody (Figure 4D) . Furthermore, positive NTs were also seen in the white matter. Intra neuronal inclusions labelled with synuclein-1 or with α-synuclein antibodies could not be detected, even though the latter antibody labelled some of the plaques. Prion protein staining did not reveal changes seen in prion diseases. Quite strong inflammatory response was noted both as numerous activated microglial cells (AM) and reactive Figure 4F ) were primarily located centrally in the plaques, whereas the RAs ( Figure 4E ) were seen more diffusely within the grey matter. Both cell types were also identified within the white matter. Moderate complement factor labelling was observed in association with the plaques with antibodies directed to the C3d factor, and weak staining with antibodies directed to C3c and C1q factors, also in association with the plaques, whereas no staining was detected with antibodies directed to the C5 complement factor.
Discussion
Recently, Crook et al 8 described a novel variant form of AD in a Finnish pedigree with spastic paraparesis and unusual eosinophilic plaques resembling cotton wool balls. These plaques showed uneven peripheral immunoreactivity for A and were not discernible from the background by Thioflavin-S. The molecular genetic basis of the variant form of AD was shown to be a deletion of exon 9 from the PS-1 mRNA, whereas no genomic DNA alteration was identified. In this present article, we have identified a novel 4.6-kb genomic deletion in the PS-1 gene in one Finnish EOAD family, which leads to the inframe exclusion of exon 9 from the mRNA transcript. Although the genomic deletion leads to a similar end result at the mRNA level as described by Crook et al, 8 the phenotypic features of the AD patients clearly resemble the typical AD rather than the variant AD. Disease-causing genomic rearrangements including large deletions, inversions or duplications, have not been previously demonstrated to occur in the EOAD genes. In contrast, germline and somatic rearrangements of the genomic DNA are frequent in various cancer types, and a common mechanism giving rise to these alterations is Alu-mediated homologous recombination. 21, 22 The well-conserved region of Alu sequences is frequently found at or close to the sites of homologous and non-homologous recombination and has been proposed to be a hot spot of recombination. 23 Also in this particular case, a complete 26 bp Alu core sequence was located near the tetranucleotide sequence TGGG shared by the both recombining fragments at the intron 8 ( Figure 3A) . In addition, a small segment upstream from the TGGG sequence displayed homology with the core sequence also in the 3' breakpoint region, indicating involvement of the Alu core element, or part of it, in both recombining fragments.
Comparison of the breakpoint regions and the nearby intron regions, however, did not reveal any major homology between 5' and 3' sequences favoring the Alu core sequencestimulated non-homologous recombination rather than the Alu-mediated homologous pairing of the fragments. Thus, in accordance with findings showing the involvement of at least one complete or partial Alu core element in the rearrangement processes, 24, 25 the present study also addresses the importance of Alu core sequence-stimulated functions in the non-homologous recombination events.
The clinical history of AD patients with the novel PS-1 ∆9 mutation did not reveal any indications of spastic paraparesis (paralysis of legs) or any other major motor-neuronal disturbances. This is crucial since spastic paraparesis is the main clinical feature associated with variant AD patients. 8 In contrast, the common clinical manifestations in AD patients described here are memory impairment and rapid progression of the disease after onset. The mean disease onset age in this EOAD family is 43.5 years, which is close to that previously reported with the ∆9 splice-site mutation family. 5 Very early onset ages (from 40 to 45 years of age) with the novel ∆9 mutation, is in agreement with the findings showing that the deletion of the PS-1 exon 9 has the greatest impact on A 42 production in various transfected cell lines 26, 27 and this is suggested to promote cerebral A deposition and induce AD. 28 In accordance with the clinical features, neuropathology was typical of AD in this family with numerous amyloid plaques with a central core formation, neurofibrillary tangles, neuritic plaques, and reactive astrocytes and microglial cells in association with the plaques. More importantly, neuropathological examination did not reveal 'cotton wool' plaques, which are the hallmark of the variant AD. The phenotypic data, therefore, suggests a clear difference between the variant AD patients with spastic paraparesis and the EOAD patients described here, although the molecular genetic basis in both cases is the abnormal splicing of exon 9. In addition to the large genomic deletion found in the PS-1 gene, a substitution E318G was detected in the exon 9 among the family members. The role of the E318G variant is controversial, since it has been reported to be causative for AD, 29 but also to be a rare polymorphism not associated with AD. 18 Our studies using the Finnish AD and control population indicate that the E318G variant is probably nonpathogenic since a small group of age-matched control subjects also carries the alteration (S Helisalmi et al, 1999, unpublished data). However, the allele frequency of the E318G variant is significantly increased in both familial and sporadic AD groups when compared with the control group, suggesting that it may be a risk factor in AD. It is possible that the variant is in linkage disequilibrium with yet another change located perhaps in the promoter or regulatory regions of the PS-1 gene. The effect of the E318G variant on this particular family could be evaluated by a suggestion made by Mehta et al. 27 The age of onset of the PS-1-caused disease could be influenced by other genetic factors contributing either in a cis-or trans-acting way. In this respect, however, the E318G variant does not seem to modulate the age of onset in this family ( Figure 1 ) and its possible role in AD remains to be determined in further studies.
In conclusion, we have identified a novel 4.6-kb genomic deletion in the PS-1 gene in a Finnish EOAD family, which leads to the exclusion of exon 9 from the PS-1 mRNA. We propose that an Alu core-stimulated non-homologous recombination event underlies this rearrangement. Moreover, we Novel 4.6-kb genomic deletion in presenilin-1 gene M Hiltunen et al y could not detect further cases with the mutation, indicating that the frequency of this novel ∆9 alteration in the Eastern Finnish AD population is low. The expression of both the wild type and truncated PS-1 transcripts probably rules out the possibility that pathogenic effects would be exerted through haploinsufficiency. Therefore, the possible mechanism of pathogenesis in this novel ∆9 mutation may be the same as previously suggested by Citron et al 28 and Ishii et al. 30 Increased production and deposition of amyloidogenic A 42 could then be the fundamental pathological determinant promoting AD. Finally, the phenotypic differences between various ∆9 mutation families suggest that there exist modifying factors, which may participate in the AD process in addition to the main causative agent.
